Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Love orcas Nice analogy
But IMHO very little of today's action was shorts
Today was word getting out finally and people wanting a postion
Then throw in the fact the chartist and technicians got involved we really moved
Closing above 200 day avg to many is a big deal. Just look on twitter for that
Lots of eyes on twitter these days and many will be looking over the weeknd for sure
Dough
TG THERAPEUTICS, INC. ladenberg
Strong Showing at ICML; Reiterate BUY and Increase PT to $26 from $22
Strong showing at ICML 2015 with three oral presentations:
Positive TG-1101 plus Ibrutinib combination Phase II trial data updated at the ICML Conference. The TG-1101 (ublituximab) + Ibrutinib combo study is a Phase II single arm study in relapsed or refractory MCL and CLL (as per the ibrutinib label). The study currently has 44 patients evaluable for safety and 40 evaluable for efficacy. The current efficacy results show an overall response rate (ORR) of 88% with 4 CRs and 35 PRs. 88% of CLL patients showed a response with 4 CRs and 31 PRs. In the high risk CLL subset, 95% of the patients responded with 3 CRs and 16 PRs. Additionally, median nodal reduction was 85% and 15% of the high risk CLL patients were MRD negative within 6 months. Importantly the combo was well tolerated with minimal Grade 3/4 events. High risk CLL patients are the target population for the planned TG-1101 + Ibrutinib Phase III study. The data show the addition of TG-1101 controls the Ibrutinib-related lymphocytosis (reduces the severity and the duration creating earlier clinical responses). We believe the 95% ORR observed in high-risk CLL is compelling and bodes well for the success of the randomized TG-1101 + Ibrutinib combo vs. Ibrutinib alone Phase III trial. Dr. Susan O’Brien presented data from a 144 patient Ibrutinib mono-therapy study in high risk CLL patients at ASH 2014 showing a 60% ORR (all PRs) based on an independent review committee assessment and a 65% ORR (63% PRs, 1% CR and 1% CRi) based on an investigator assessment.
Robust triple combination therapy results presented at ICML. Dr. Loretta Nastoupil (MD Anderson) presented updated data from TG’s ongoing triple combination trial of TG-1101 (glycoengineered anti-CD20 mAb) in combination with TGR-1202 (PI3k Delta Inhibitor) and Ibrutinib (BTK inhibitor) in patients with B-cell malignancies. The TG-1101 plus TGR-1202 plus Ibrutinib triple combo study is a dose escalation PI/Ib trial, which is enrolling heavily pre-treated relapsed or refractory B-cell lymphoma (NHL and CLL) patients. The data show the triple combination was safe and well tolerated with no patients discontinuing treatment due to an AE and Grade 3/4 events observed in only 6% of patients. The triple combo was highly active in this heavily pretreated patient population with 100% of the CLL/SLL and 75% of the iNHL (FL/MZL) patients showing a PR or CR (including a durable PR in an Ibrutinib refractory FL patient). The data from the dose-escalation cohorts (TGR-1202 dose escalation) show the triple combination is highly active with ORR of 100% in CLL/SLL and 75% in iNHL. Importantly, responses were rapid in the majority of patients with a 76% median reduction in nodal disease observed at the first assessment (week 8) in responders and responses deepened on later assessments (week 20) with a 92% median reduction observed. The triple combo study continues to accrue patients and Phase 2 studies are planned in multiple B-cell tumor types. We are impressed by the tolerability of the triple combo and with the level of activity observed in this highly pre-treated relapsed-refractory patient population and we look forward to additional results from this trial in 2015.
We reiterate our Buy rating and increase our price target to $26 from $22. We are increasing our price target based on the data presented during June 2015 at ASCO, EHA and ICML showing TGR-1202’s differentiated (cleaner) side effect profile which could make the compound easier to use in combination therapy.
From simon bramfitt
@SimonBramfitt: @ahagelthrope @dougheuringaria Best to say that MS recognition of @Sphere3D's merit is of more value than anything I might offer
great place for MSFT to talk $ANY
http://www.clocate.com/conference/Microsoft-Wolrdwide-Partner-Conference-WPC-2015/14463/
Microsoft Wolrdwide Partner Conference (WPC 2015) covers topics such as:
¦Software Development
¦Corporate Accounts
¦Future of Productivity
¦Distributors and Enterprise Partners
¦Independent Software Vendors (ISV)
¦Hosting and Cloud Service Providers
¦Large Account Resellers (LAR)
¦Industry—Distribution, Finance, Manufacturing
¦Original Equipment Manufacturer (OEM)
¦Learning Solutions
¦Resellers
¦Public Sector
¦Software Asset Management (SAM)
¦Small and Midsize Business (SMB)
¦System Integrators
¦Business Leadership/Sales Excellence/Marketing
¦Windows Phone
¦Windows Client
Microsoft Wolrdwide Partner Conference (WPC 2015) brings together Partners, Microsoft employees, Associates, MVPs, software Architects, IT Professionals and software Developers.
Bodes well for there phase 3 reg trial
121 sites now recruiting
FGEN RBC comments today. hosted investor meetings for 2 days and acknowledge a rejuvenated interest in FGEN after the recent pullback. We think the recent pullback provides an attractive opportunity for long-term investors to re-evaluate FGEN given two blockbuster programs advancing in 2015-16 and we think investors will come back to this name as data gets closer over time.
• FGEN went public over a year ago and was up over 100% through early 2015 due to a potential big opportunity for a $2-4B oral anemia pill (roxadustat) that could become a major competitive and attractive economic option for dialysis centers in the CKD market using EPO, and a big call option in the non- dialysis market which is 2x as big and not practical for EPO vs attractiveness for an oral pill option. This has marched ahead into global Phase III trials and enrollment is on track with two major pharma partners, AZN and Astellas.
• After a lock-up release May 13th after being private for 20 years, the stock has come back in and we think found a floor in the $18-20 range back near IPO price. Yet this is where we think long-term investors should be doing work and thinking about the next 18-24 months of value creation: 1) stock has 30% of its value in cash, 2) Phase III anemia is a year more enrollment and maturity and safety, and 3) the under-the-radar call option is the fibrosis antibody FG-3019 that wasn’t a focus a year ago but now that it’s going to be developed into three indications and data over the next 12-18 months, this is a long-term big opportunity that few investors are paying attention to and isn’t in Street consensus estimates.
Pullback is opportunity to start paying attention to
anemia pill and fibrosis antibo
Cormark report details 9 dollar target https://twitter.com/dougheuringaria/status/610877972401270784
akeaways From Investor Briefing
We attended Sphere 3D investor/analyst briefing yesterday in which the company provided its strategic growth plan to position itself in the hybrid cloud while it showcased its latest virtualization, storage and data management products and solutions. In particular, the session included a keynote from Mr. Larry Orecklin, VP, Chief Evangelist of Microsoft where he emphasized the importance of its partnership with Sphere to its Azure platform. The bottom line, we believe Sphere’s investor briefing which showcased its new solutions reinforced our view on the name where the company is entering a new product cycle that should drive renewed revenue growth but against a rebased and more efficient cost base. This combination should have the company take advantage of leverage and reach an inflection point of improving margins and positive cash flows. We continue to value Sphere 3D using a DCF analysis to capture the growth profile of the combined company beyond the product and sales integration period. Our analysis points to $9.00 target price. We have a Buy (S) recommendation.
attended Sphere 3D investor/analyst briefing yesterday in which the company provided its strategic growth plan to position itself in the hybrid cloud, while it showcased its latest virtualization, storage and data management products and solutions. In particular, the session included a keynote from Mr. Larry Orecklin, VP, Chief Evangelist of Microsoft where he emphasized the importance of its partnership with Sphere to its Azure platform.
Supporting Microsoft In Hybrid Cloud: With Sphere being in a product transition phase, we believe it was insightful to hear firsthand from a member of the Microsoft team (Mr. Larry Orecklin) speaking on the significance of its technology and sales partnership with Sphere. Specifically, Mr. Orecklin highlighted the use of Sphere’s technology in extending the capabilities of the Azure platform that Microsoft otherwise could not do on its own, particularly on enabling the hybrid cloud model, whether it be on-premise, in the cloud, or some combination of both with scalability being one of the key benefits. Recall, Sphere and Microsoft entered into a strategic collaboration earlier this year to enable support of Glassware on Microsoft Azure. The two companies are working together to simplify businesses’ migration of existing Windows-based applications from physical infrastructure to the Azure cloud and while they are targeting various verticals, the education market has been the initial target market. On that note, New Caney ISD, an independent school district in Texas, US, is a customer of Sphere and Microsoft with Mr. Orecklin indicating that the two companies were able to help New Caney transition to the hybrid cloud supporting 10K devices as it was unable to make the shift on its own given the limitation of its infrastructure that was not cost effective and would have made it uneconomical.
Ramping Up New Product Cycle: With the closing of its acquisition of Overland Storage, Sphere has been ramping up new integrated product solutions to target the converged infrastructure market in virtualization, data management and storage. Recall, the two companies had been working together for some time (close to two years) given their previous technology and reseller partnership that has Sphere expecting increased product launches mid this year, and based on the investor event, we believe the company is on track to that plan. Specifically, the company highlighted its Glassware and SnapCLOUD, an enterprise-class virtual storage platform with both already being hybrid cloud (on-premise and in the cloud) enabled and having the ability to support Microsoft’s Azure platform. Sphere has already begun to target a number of market verticals such as healthcare and government in addition to education. In healthcare, the company recently announced a new and its largest supply agreement with Novarad to deliver its Glassware, V3 and storage solutions to 400 healthcare facilities in the US that is expected to begin deployment in Q3/15.
Bottom Line: We believe Sphere’s investor briefing which showcased its new solutions reinforced our view on the name where the company is entering a new product cycle that should drive renewed revenue growth but against a rebased and more efficient cost base. This combination should have the company take advantage of leverage and reach an inflection point of improving margins and positive cash flows. We continue to value Sphere 3D using a DCF analysis to capture the growth profile of the combined company beyond the product and sales integration period. Our analysis points to $9.00 target price. We have a Buy (S) recommendation. While we believe the potential disruptive nature of Sphere’s technology has potential meaningful value (greater than the current value), the limited record of operating execution and Overland’s history of losses despite our view of a positive turn in profitability point to a considerable level of operating risk and as such we would underscore the speculative risk on this name.
Nice blog but clearly they never heard of
Snapcloud as MSFT azure has. Nutanix either no
Cloud capabilities. http://www.briefingsdirectblog.com/2015/05/enterprises-opting-for-converged.html?m=1
Trying to get the word out. https://twitter.com/dougheuringaria/status/609327171270619137
Glassware History and Vision
Glassware 2.0 found its beginnings in 2009 as a technology that was created to deliver a fully functioning Android environment to online PCs. That one basic problem premise led to years of development, culminating with the first demonstration of Microsoft Excel on an iPad in 2011. At that point, management realized the importance of what had been created and shortly thereafter, Sphere 3D took aim at delivering the first purpose built application virtualization technology.
Although our thoughts on the best way to commercialize the technology have changed, Glassware has not. At first we thought we had built a way for consumers to view PC applications on a tablet or phone but after taking our software out for a spin with some potential customers, we realized we had much more than that. Glassware had this ability to virtualize apps that to date, had not been virtualizable; and there are many of them. We found an enormous under-serviced market for legacy software applications that we could address; from the likes of Windows XP to proprietary mainframe applications.
Substantially more users per CPU for Windows applications!
As we continued to test the limits of Glassware, we found out how efficient it was, allowing substantially more users per CPU for Windows applications than traditional hypervisor based virtualization solutions.
We thought about why the desktop exists and started building APIs between the applications running on Glassware. Through these APIs we can deliver a portal with a suite of different applications that can talk to each other, and share data. In other words, we built the desktop workflow without all that unnecessary desktop operating system software and without the need for most of the compute that exists for desktops today.
We have prototyped uniting the server and the local device. In other words we placed Glassware on a laptop and had it act as both server and user device. This could enable software applications to run on a very lightweight device because of the efficiency gained from our Microvisor.
We thought if we can do this with a laptop, how far can we go? We put Glassware on a small chipset with some storage attached (it fit in the palm of your hand). We connected it to a display and a keyboard, and voila we had the beginnings of Glassware on a chip.
We believe in a future where a person could walk around with inexpensive commodity devices that run any software from any operating system or chipset and leverage the cloud for additional horsepower when needed.
Perhaps one day, in a pinch, you could take over the CPU of your refrigerator, stream the display to your TV and use your phone to enter data into your impromptu computer. The third world would never throw another computer chip away again. It could be endlessly recycled as a dumb CPU used by our Glassware 2.0 Protocol.
We know we have some doubters- but that’s ok. Before all the cool, world changing stuff, we need to continue to virtualize the unvirtualizable Windows apps- an app at a time. Come check out our technology and see what it might imply for the future.
@pbookman: Great stuff about Sphere 3D and one of our customers from New Caney that is using our solutions for moving from... http://t.co/oWd9duRIcP
@pbookman: Dustin Hardin shares how easy it was to deploy our Sphere 3D Glassware technology to install applications and... http://t.co/mG8XkZb7Bx
2 heavy hitters looking at $ANY chart 35000 followers
Between 2 of them
Some $ANY action here... big level at 4.6 it looks technically..... pic.twitter.com/TXUol1cynj
— kkern (@kkernttb) June 10, 2015
@stt2318 Inverted H&S there too
— Woll Street (@paulwoll) June 10, 2015
JFM nice post big nugget on there
Basically $ANY solves the XP problem. No brainer
For MSFT to be key partner IMHO
Out today. Azure a pillar. $ANY right place at right time
We are initiating coverage of Microsoft Corporation (MSFT) with a Hold rating and $52 price target. Satya Nadella was promoted to CEO in February 2014, and was challenged to transition Microsoft from a monopolistic Windows company to a new-age mobile, cloud first world, which will likely include moving away from up-front license contracts to a more subscription/ratable revenue model. We believe this strategic transition should make the company stronger over the long term while improving both revenue growth and margins. In our opinion, MSFT's cloud platform Azure and cloud applications such as office 365 are under-appreciated and will likely be key pillars to MSFT growth going forward
Not very of term on Wall Street the message
Is this clear. @dougheuringaria: @ScottShaffer $ANY one stop shop cloud computing & $MSFT where new CEO Nadella has made cloud revenue his toppriority http://t.co/uIVDl10MMd
https://twitter.com/dougheuringaria/status/608043853417873409
MSFT 80 billion in revenues
Sheldon Sheldon Sheldon Sheldon ole my would
100000 share market order right about now blow
Shut the shorts up.
RBC Fast-Growing and Differentiated Player in Wound Care: Initiating at Outperform
Our view: ALQA is an emerging wound care company, with a highly differentiated product portfolio that addresses a $5 billion TAM. Led by two unique products, Biovance and MIST, and one of the most experienced management teams in wound care, we believe that ALQA will be one of the faster growing companies in small-cap MedTech.
Key points:
• Advanced Wound Care is one of the faster growing segments of MedTech and ALQA is well positioned to take significant market share. We estimate that the advanced wound care market in the U.S. for ALQA is a ~$5B market opportunity growing in the high-single digits to low- double digits. We estimate that ALQA holds less than 1% share. Given a fragmented competitive landscape and ALQA’s presence in the faster- growing sub-segments of wound care, we believe that the company is well positioned for significant revenue growth and share gains. We project full-year 2015 revenues of ~$17.1M, which represents ~260% y/ y growth (~130% y/y organic), going to $31.3M in 2016 (up ~83% y/y, ~54% y/y organic). Beyond 2016, we believe ALQA’s advanced wound care portfolio should deliver ~50% revenue growth, before acquisitions.
• Biovance and MIST are highly differentiated advanced wound care products, and revenues for both products are poised to take off given recent favorable reimbursement decisions. We believe that Biovance, licensed from Celgene, as well as the MIST Therapy system (from the Celleration acquisition) represent two of the most unique products in the advanced wound care market. More importantly, both products just received favorable reimbursement decisions that should drive accelerated growth in the next two to three years. For Biovance, Novitas just started reimbursing (~25% of total covered lives), and we expect additional MACs to follow over the next 12 months. For MIST, reimbursement was increased on January 1 (increased by ~75%) that should drive greater utilization. We believe that both products have peak sales potential of $500M+.
• Best-in-class management team at the helm with significant experience in building a wound care company. ALQA has a talented and seasoned management team, led by Dave Johnson, CEO. Dave Johnson and his top executives previously helped build ConvaTec into a wound care company with ~$1.7B in annual sales, guiding the company in strategy, sales, marketing, and operations. Under Mr. Johnson’s guidance, ConvaTec tripled its revenue base before the company was sold to private equity. We believe that Mr. Johnson and his management team understand the wound care market, have gained exposure to the faster-growing segments of the market, and have the capabilities to repeat what they did at ConvaTec to build ALQA into one of the fastest growing players in wound care.
Thanks I made tweet of your find. https://twitter.com/dougheuringaria/status/607244622469853184
I tweeted your info good stuff https://twitter.com/dougheuringaria/status/607019970568945664
Thanks to ahagelthrope for helping put together.
https://twitter.com/dougheuringaria/status/606870357908127746
@ch9: Live from Microsoft Ignite: Mark Russinovich - Technology Introspective | Edge http://t.co/g5VvkArLv1
http://azure.microsoft.com/blog/2015/05/26/azure-storage-talks-from-build-ignite/
Windows 10 Could Provide Incremental Help to a Weak PC Market. During the Microsoft Forum, Microsoft focused on Windows 10, and we walked away with a favorable impression of the new OS that could provide some help to a struggling PC market in the later part of the year. Learning from the mistakes of Windows 8 and adapting to the times, Microsoft decided to make changes with Windows 10 with three, high level differences. First of all, Windows 10 will include a universal application platform across all devices. Secondly, Microsoft will provide ongoing OS updates. Finally, the company invested in a free upgrade initiative that provides a free upgrade to Windows 10 for eligible users. With Windows 10 planned for launch on July 29, the company's goal is to ramp to 1 billion Windows 10 users over the next three years versus a current Windows installed base of 1.5 billion today. In our coverage universe, Hewlett-Packard (30% of 2Q:FY15 sales) is the largest PC vendor and a potential beneficiary of a favorable Windows 10 cycle.
Can you share anymore details of 8-11 mgrs??
I am currently talking to JMP analyst trying to
Get him to go June 15
RBC on MSFT WecameawayfromourrecentvisittoMicrosoft'scampuswith a more positive view on medium-term gross margins for Azure, the sustainability of growth in Server licensing and consumer Windows pricing under W10. We recently visited management at Microsoft's campus. We reiterate our OP and $54PT.
• A more positive view on medium-term gross margins for Azure: Microsoft is optimistic that at the same revenue scale, Azure should be more profitable than AWS due to the premium workloads in the Azure mix.
• Sustained growth for Server Licensing: Microsoft remains confident in its ability to grow Server licensing revenue, despite investorfearsthatpricetailwindswilldiminishand,ultimately, Azure will cannibalize on-premise workloads.
• Windows 10 consumer pricing: Microsoft does not expect the same magnitude of revenue per license declines on non-Pro SKUs that it saw in FY15. We view this as a significant positive in the context of our model that currently assumes a -20% decline in Non-Pro Windows revenue in FY16.
North email me ariadough@gmail.com if you need more $ANY info
Dough
North40000 nice to see you hear. Dough
: Larry Orecklin, VP, Chief Evangelist, of $MSFT to give Keynote speech at @Sphere3D $ANY Investor Event June 15 NYC.
@markrussinovich: Looking forward to sharing info on Azure networking innovations in my Open Networking Summit keynote in a few weeks http://t.co/XVj3wVOvKC
@struftepete @Sphere3D Now that you mention it, we do! Try this. http://t.co/J19Sp8jfsr #NovaGlass #VDI #healthcare
— Novarad (@NovaradCorp) June 2, 2015
TGTX brean. Best safety profile in its class
1101 And 1202 ORR Continues To Improve Over Time -
Next Phase 3s Start By YE15
Investment Summary
Yesterday, TG updated its TG-1101/TGR-1202 dual therapy trial and its TGR-1202 monotherapy trial, continuing to show the drugs’ utility in advanced lymphomas. We note for TGR-1202, increased dose brings increased efficacy, but little increased toxicity. We look forward to the company starting at least two more Phase 3 trials involving these drugs by YE15, which is a few months later than we expected the first one to start, but not at all concerning to us. We also look forward to today’s oral presentation of the triplet regimen (TG-1101, TGR-1202, and ibrutinib). Regarding the dual therapy, 55 patients were evaluable for safety (up from 32 in the abstract), with neutropenia (27%; 24% Grade 3/4; a decrease vs the abstract’s 41%; 31% Grade 3/4) as the most serious toxicity, but still no signs of hepatotoxicity or colitis. Updated efficacy draws from 39 evaluable patients, up from 28 in the abstract, and we note that all 13 CLL and SLL patients evaluable for efficacy remain progression free, regardless of TGR-1202 dose, versus all 10 in the abstract, with 9 of them responding. Regarding TGR-1202 monotherapy, 66 patients were evaluable for safety (up from 58 in the abstract), with the only Grade 3/4 AE in >10% of patients being an 11% rate of neutropenia. As with the dual therapy, monotherapy also showed a strong dose response, with higher doses yielding responses in 6 of 7 CLL patients, and in 3 of 6 FL patients, but without obvious dose related toxicity.
Discussion
Yesterday, TG Therapeutics updated its TG-1101/TGR-1202 dual therapy trial as well as its TGR-1202 monotherapy trial, continuing to show the utility of its drugs in advanced lymphomas. We note for TGR-1202, increased dose brings increased efficacy, but little increased toxicity. We look forward to the company starting at least two more Phase 3 trials involving these drugs by YE15, which is a few months later than we expected the first one to start, but not at all concerning to us. We also look forward to today’s oral presentation of the triplet regimen (TG-1101, TGR-1202, and ibrutinib).
TG-1101 and TGR-1202
55 patients were evaluable for safety (up from 32 in the abstract), with neutropenia (27%; 24% Grade 3/4; a decrease vs the abstract’s 41%; 31% Grade 3/4) as the most serious toxicity, but still no signs of hepatotoxicity or colitis. We note that the trial allowed for patients with Grade 3 neutropenia to enroll, and that the single case of Grade 4 neutropenia (a DLT) occurred in a patient with Grade 3 at baseline. 18 patients have been on therapy for 6+ months (9 for over a year) with no observed colitis, and only 3 patients discontinued due to an AE (but none on >=800mg micronized TGR-1202). Only 29% of patients had a day 1 Grade 1/2 injection site reaction. Despite the advanced stage of these patients (no limit on prior therapy), the dual regimen appears to be very well tolerated. The clean safety profile is particularly important in that it more easily allows for combining this dual therapy with other agents, like ibrutinib and TG’s IRAK4 inhibitor.
Updated efficacy draws from 39 evaluable patients, up from 28 in the abstract, and we note that all 13 CLL and SLL patients evaluable for efficacy remain progression free, regardless of TGR-1202 dose, versus all 10 in the abstract, with 9 of them responding (1CR/8PR). Higher doses of TGR-1202 are clearly more effective in treating rel/ref DLBCL, FL, MZL, and Richter’s patients, and that ORR increases over time, with 3 of the 5 CRs in the trial being observed at later time points. We note that the one Richter’s patient achieved a PR, which differs from the abstract. At higher TGR-1202 doses, 7 of 11 indolent lymphoma patients responded, as did 3 of 6 with DLBCL, and 5 of 6 with CLL/SLL.
TGR-1202 Monotherapy
66 patients were evaluable for safety (up from 58 in the abstract), with the only Grade 3/4 AE in >10% of patients being an 11% rate of neutropenia. By contrast to other PI3Kd inhibitors, there was only one Grade 3/4 diarrhea, and it only lasted 2 days without dose interruption/ reduction. Most importantly, there was no hepatotoxicity or colitis, with 37 patients exposed to >=800mg micronized TGR-1202 and 19 of them for more than 6 months. Among all doses, 29 of 66 patients have received therapy for 6+ months, with 3 on therapy for 2+ years, and less than 5% of patients discontinued due to an AE. We believe that it is fair to compare early TGR-1202 trials with the far more extensive Zydelig clinical experience because Zydelig was associated with significant gastrointestinal adverse events even early in development. We note that 55% of patients were exposed to >=3 prior regimens, underscoring TGR-1202’s safety as well as efficacy. Dose expansion cohorts continue to enroll at micronized doses of 800mg and 1200mg.
As with the dual therapy, monotherapy also showed a strong dose response, with higher doses yielding responses (nodal PRs) in 6 of 7 CLL patients, and in 3 of 6 FL patients (PRs), but without an obvious increase in toxicity as dosing increased. Among all doses, 14 of 16 CLL patients achieved a nodal PR (versus 13 of 14 in the abstract), with the remaining 2 still on therapy with a lesser response, and 10 of the 16 achieved a PR per iwCLL (Hallek 2008) criteria. Also, 10 of 12 FL patients had tumor reduction, with 5 of them achieving PR. We expect responses with the single agent to also improve over time.
EMC Acquisition of Virtustream for $1.2 Billion: Long Term Positive, Short Term Negative; Reiterate Neutral, $28 Target Price
? Our View – Near term this is not a positive for investors but long term is a positive for the following reasons. Near term this greatly reduces the probability of an accelerated stock buy back as well as supports our view that EMC is unlikely to break the company up (opposite of shareholder activists desire) and investors will be disappointed in the lack of financial details about privately-held Virtustream (no sales, margins, or EPS accretion details or methodology for determining the sales price). Long term this is a positive as the transaction better positions EMC’s cloud computing and hybrid solutions. We also note EMC will keep its Virtustream business as a standalone EMC operated company within the federation, which we believe enables to EMC to possibly monetize this in the future (for example IPO, sale, divestiture, etc.).
? Details – $1.2 billion all cash price acquisition expected to lose in Q3 2015. EMC stated the transaction will be additive to sales and accretive to EPS in 2016. Neither company would provide sales or margin details other than to state 60% y/y growth in Q1. While details are not available we expect the annual sales are materially below $500m.
? Stock Call – We maintain our Neutral rating (67% Buy ratings by sell-side, albeit down from 79% a year ago) and $28 target as we look for signs of structural reacceleration in storage spend to reconsider our rating. EMC shares are currently trading at 14x F12M PE (10x NTM PE for core-EMC) which we view as reasonable and look for a potential pull-back and better entry-point. We do not believe EMC will break itself up.
SE great post. Best of year IMHO. I tweeted it
Please everyone retweet this lets get it out to others
https://twitter.com/dougheuringaria/status/601222737013575680
Huge call by awesome calls. https://twitter.com/super_trades/status/601023245152686080
$ANY
Must read
Please take a look at my latest blog which begins to compare @Sphere3D Glassware technology to Docker Hint: Windows http://t.co/m8qnSqILrW
— Peter Bookman (@pbookman) May 18, 2015
Please take a look at my latest blog which begins to compare @Sphere3D Glassware technology to Docker Hint: Windows http://t.co/m8qnSqILrW
— Peter Bookman (@pbookman) May 13, 2015
One thing about shorts 400k today 275 yesterday
Very well could been some in the know of funding
Taking place. They shorted knowing of it or would
Be taking a part of it?????
Is roth doing it????
Very good days ahead
Virtualization Capabilities to 400 Healthcare Facilities
400 facilities buying
will include a combination of virtualization technologies including the award-winning V3 hyper-converged platform, Glassware 2.0, and SnapScale(R) and SnapServer(R) lines of storage products
Huge volume. Shorts in real trouble here
FYI. Docker CEO on cnbc today.